• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5090571)   Today's Articles (0)
For: Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019;4:341-353. [PMID: 30824404 DOI: 10.1016/s2468-1253(19)30012-3] [Citation(s) in RCA: 443] [Impact Index Per Article: 73.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2018] [Revised: 12/13/2018] [Accepted: 12/18/2018] [Indexed: 12/19/2022]
Number Cited by Other Article(s)
1
Lundekvam JA, Høivik ML, Anisdahl K, Småstuen MC, Warren DJ, Bolstad N, Medhus AW. Tumour necrosis factor inhibitors in Ulcerative colitis: real-world data on Therapeutic drug monitoring and evaluation of current treatment targets (STRIDE II). Ann Med 2025;57:2424447. [PMID: 39757985 PMCID: PMC11721610 DOI: 10.1080/07853890.2024.2424447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Revised: 12/31/2023] [Accepted: 08/31/2024] [Indexed: 01/07/2025]  Open
2
Li X, Song FL, He HF, Zeng SM, Feng ZC, Rong PF. Longitudinal computed tomography-based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn’s disease patients. World J Gastroenterol 2025;31:105895. [DOI: 10.3748/wjg.v31.i21.105895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2025] [Revised: 04/05/2025] [Accepted: 05/21/2025] [Indexed: 06/06/2025]  Open
3
Nardone OM, Vuyyuru SK, Yuan Y, Hanzel J, Jairath V. Differentiating IL-23 Inhibitors in Crohn's Disease. Drugs 2025;85:725-740. [PMID: 40323342 DOI: 10.1007/s40265-025-02183-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/07/2025] [Indexed: 05/24/2025]
4
Song JH, Hong SN, Kim MG, Kim M, Kim SK, Kim ER, Chang DK, Kim YH. Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study. Gut Liver 2025;19:376-387. [PMID: 40254990 PMCID: PMC12070208 DOI: 10.5009/gnl240503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2024] [Revised: 02/03/2025] [Accepted: 02/04/2025] [Indexed: 04/22/2025]  Open
5
Anjie SI, Gecse KB, Meloni CM, Vidal-Itriago A, Löwenberg M, D'Haens GR. Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2025:S1542-3565(25)00409-4. [PMID: 40378993 DOI: 10.1016/j.cgh.2025.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2024] [Revised: 02/28/2025] [Accepted: 03/04/2025] [Indexed: 05/19/2025]
6
Zhao M, Larsen L, Dige A, Poulsen A, Lo B, Attauabi M, Ovesen PD, Wewer MD, Christiansen D, Hvas CL, Petersen AM, Bendtsen F, Seidelin J, Burisch J. Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease-A Prospective Multicenter Cohort Study. J Crohns Colitis 2025;19:jjae192. [PMID: 39700468 DOI: 10.1093/ecco-jcc/jjae192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2024] [Revised: 12/05/2024] [Accepted: 12/18/2024] [Indexed: 12/21/2024]
7
Teichert C, Anjie SI, Stevens TW, Bahur B, Bray KR, Gecse KB, D'Haens GR. Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response. Inflamm Bowel Dis 2025:izaf101. [PMID: 40334112 DOI: 10.1093/ibd/izaf101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2025] [Indexed: 05/09/2025]
8
Temido MJ, Honap S, Jairath V, Vermeire S, Danese S, Portela F, Peyrin-Biroulet L. Overcoming the challenges of overtreating and undertreating inflammatory bowel disease. Lancet Gastroenterol Hepatol 2025;10:462-474. [PMID: 39919770 DOI: 10.1016/s2468-1253(24)00355-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2024] [Revised: 10/20/2024] [Accepted: 10/22/2024] [Indexed: 02/09/2025]
9
Kim SM, Oh H, Hong SN, Kim MJ, Choe YH, Lee SY. A Bottom-Up Liquid Chromatography-Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Infliximab: Method Development, Comparison With 2 Enzyme-Linked Immunosorbent Assay Methods, and Evaluation of Anti-Drug Antibody Interference. Arch Pathol Lab Med 2025;149:448-456. [PMID: 39041105 DOI: 10.5858/arpa.2023-0573-oa] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/06/2024] [Indexed: 07/24/2024]
10
Schreiber S, Colombel JF, Hanauer SB, Sandborn WJ, Danese S, Lee SJ, Kim SH, Bae YJ, Lee SH, Lee SG, Lee JH, Kim JM, Park GH, Lee J, Lee JH, Kim CY, Sands BE. Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis 2025:izaf038. [PMID: 40300779 DOI: 10.1093/ibd/izaf038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2024] [Indexed: 05/01/2025]
11
Stankey CT, Lee JC. The Role of ETS2 in Macrophage Inflammation. DNA Cell Biol 2025. [PMID: 40227609 DOI: 10.1089/dna.2025.0064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/15/2025]  Open
12
Doherty J, Ryan AW, Quinn E, Conroy J, Dolan J, Corcoran R, Hara FO, Cullen G, Sheridan J, Bailey Y, Dunne C, Hartery K, McNamara D, Doherty GA, Kevans D. HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease. Inflamm Bowel Dis 2025;31:903-911. [PMID: 38937958 DOI: 10.1093/ibd/izae138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Indexed: 06/29/2024]
13
Peruhova M, Stoyanova D, Miteva DG, Kitanova M, Mirchev MB, Velikova T. Genetic factors that predict response and failure of biologic therapy in inflammatory bowel disease. World J Exp Med 2025;15:97404. [PMID: 40115750 PMCID: PMC11718585 DOI: 10.5493/wjem.v15.i1.97404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2024] [Revised: 10/09/2024] [Accepted: 11/14/2024] [Indexed: 12/26/2024]  Open
14
Rueda García JL, Suárez-Ferrer C, Amiama Roig C, García Ramírez L, García Rojas C, Martín-Arranz E, Poza Cordón J, Sánchez Azofra M, Noci J, Cubillo García C, Martín-Arranz MD. Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn's Disease. Therap Adv Gastroenterol 2025;18:17562848251324226. [PMID: 40110342 PMCID: PMC11921000 DOI: 10.1177/17562848251324226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2024] [Accepted: 02/12/2025] [Indexed: 03/22/2025]  Open
15
Shubow S, Gunsior M, Rosenberg A, Wang YM, Altepeter T, Guinn D, Rajabiabhari M, Kotarek J, Mould DR, Zhou H, Cheifetz AS, Garces S, Chevalier R, Gavan S, Trusheim MR, Rispens T, Bray K, Partridge MA. Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop Report. AAPS J 2025;27:62. [PMID: 40087239 DOI: 10.1208/s12248-025-01050-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2025] [Accepted: 02/23/2025] [Indexed: 03/17/2025]  Open
16
Samanta A, Srivastava A. Biologics in the management of pediatric inflammatory bowel disease: When and what to choose. World J Clin Pediatr 2025;14:100938. [PMID: 40059900 PMCID: PMC11686582 DOI: 10.5409/wjcp.v14.i1.100938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Revised: 11/14/2024] [Accepted: 12/02/2024] [Indexed: 12/20/2024]  Open
17
Wang J, Guay H, Chang D. Crohn's Disease and Ulcerative Colitis Share 2 Molecular Subtypes With Different Mechanisms and Drug Responses. J Crohns Colitis 2025;19:jjae152. [PMID: 39361323 DOI: 10.1093/ecco-jcc/jjae152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2024] [Revised: 09/04/2024] [Accepted: 10/02/2024] [Indexed: 03/29/2025]
18
Durham K, Atagozli T, Elliott DE, Ince MN. Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice. Biomedicines 2025;13:491. [PMID: 40002904 PMCID: PMC11852734 DOI: 10.3390/biomedicines13020491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2024] [Revised: 01/25/2025] [Accepted: 01/30/2025] [Indexed: 02/27/2025]  Open
19
Atay A, Cagir Y, Ergul M, Ozturk O, Durak MB, Yuksel I. Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment. J Clin Med 2025;14:1228. [PMID: 40004757 PMCID: PMC11857063 DOI: 10.3390/jcm14041228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2025] [Revised: 02/07/2025] [Accepted: 02/11/2025] [Indexed: 02/27/2025]  Open
20
Shehab M, Alrashed F. Age as a Predictor of Serum Tumor Necrosis Factor Antagonist Drug and Antidrug Antibody Concentrations in Inflammatory Bowel Disease-A Nationwide Cohort Study. J Clin Med 2025;14:1057. [PMID: 40004589 PMCID: PMC11856510 DOI: 10.3390/jcm14041057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2025] [Revised: 01/29/2025] [Accepted: 02/06/2025] [Indexed: 02/27/2025]  Open
21
Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, Danese S. Understanding the therapeutic toolkit for inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2025:10.1038/s41575-024-01035-7. [PMID: 39891014 DOI: 10.1038/s41575-024-01035-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/19/2024] [Indexed: 02/03/2025]
22
Chen HC, Shunyakova J, Reddy AK, Pandiri S, Hassman L. Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis. FRONTIERS IN OPHTHALMOLOGY 2025;5:1432935. [PMID: 39936006 PMCID: PMC11810949 DOI: 10.3389/fopht.2025.1432935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/15/2024] [Accepted: 01/10/2025] [Indexed: 02/13/2025]
23
Reppell M, Zheng X, Dreher I, Blaes J, Regan E, Haslberger T, Guay H, Pivorunas V, Smaoui N. HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn's Disease Studies. J Crohns Colitis 2025;19:jjae129. [PMID: 39162746 PMCID: PMC11725519 DOI: 10.1093/ecco-jcc/jjae129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2024] [Revised: 07/17/2024] [Accepted: 08/16/2024] [Indexed: 08/21/2024]
24
Mansouri P, Mansouri P, Behmard E, Najafipour S, Kouhpayeh A, Farjadfar A. Novel targets for mucosal healing in inflammatory bowel disease therapy. Int Immunopharmacol 2025;144:113544. [PMID: 39571265 DOI: 10.1016/j.intimp.2024.113544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2024] [Revised: 10/13/2024] [Accepted: 10/28/2024] [Indexed: 12/15/2024]
25
Xiao P, Chen Z, Cai X, Xia W, Liu X, Song Z, Wang H, Zhao Y, Huang Y, Zhang Y, Guo K, Chen H, Liu R, Meng C, Fang Y, Lu Y, Cao Q. Targeting hyaluronan synthesis enhances the therapeutic effectiveness of biologics in inflammatory bowel disease. JCI Insight 2025;10:e180425. [PMID: 39782690 PMCID: PMC11721290 DOI: 10.1172/jci.insight.180425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Accepted: 11/13/2024] [Indexed: 01/12/2025]  Open
26
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. J Clin Gastroenterol 2025;59:77-81. [PMID: 38300529 DOI: 10.1097/mcg.0000000000001978] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 01/07/2024] [Indexed: 02/02/2024]
27
Nielsen OH, Hammerhøj A, Ainsworth MA, Gubatan J, D'Haens G. Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations. Drugs 2025;85:67-85. [PMID: 39532820 DOI: 10.1007/s40265-024-02115-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/15/2024] [Indexed: 11/16/2024]
28
Bourgonje AR, Dubinsky MC, Keizer RJ, Dreesen E, Mian P. Model-informed precision dosing in inflammatory bowel diseases. Trends Pharmacol Sci 2025;46:9-19. [PMID: 39632196 DOI: 10.1016/j.tips.2024.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2024] [Revised: 10/24/2024] [Accepted: 11/08/2024] [Indexed: 12/07/2024]
29
Kumar NN, Ahmad Dit Al Hakim S, Grygiel-Górniak B. Antinuclear Antibodies in Non-Rheumatic Diseases. Arch Immunol Ther Exp (Warsz) 2025;73:aite-2025-0004. [PMID: 39827475 DOI: 10.2478/aite-2025-0004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2024] [Accepted: 11/04/2024] [Indexed: 01/22/2025]
30
Genaro LM, Carron J, de Castro MM, Franceschini APMDF, Lourenço GJ, da Cruz CKNV, Reis GFSR, Pascoal LB, Mello JDC, Pereira IM, Nascimento ML, Oliveira PDSP, Corona LP, Ayrizono MDLS, Lima CSP, Leal RF. Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn's disease patients. Int J Immunopathol Pharmacol 2025;39:3946320251319379. [PMID: 39959979 PMCID: PMC11831650 DOI: 10.1177/03946320251319379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2024] [Accepted: 01/24/2025] [Indexed: 02/20/2025]  Open
31
Chen Y, Wang F, Xu L, Ke Q, Ji S, Mao J, Jia X, Lai C, Dai S. Atypical Presentation of Small Bowel Crohn's Disease: Case Report of Musculoskeletal and Hepatic Complications Without Gastrointestinal Symptoms. J Inflamm Res 2024;17:11129-11135. [PMID: 39713720 PMCID: PMC11660654 DOI: 10.2147/jir.s500687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2024] [Accepted: 12/10/2024] [Indexed: 12/24/2024]  Open
32
Clemente Bautista S, Segarra Cantón Ó, Padullés-Zamora N, García García S, Álvarez Beltrán M, Larrosa García M, Cabañas Poy MJ, Sanz-Martínez MT, Vázquez A, Gorgas Torner MQ, Miarons M. Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study. Pharmaceutics 2024;16:1577. [PMID: 39771556 PMCID: PMC11678755 DOI: 10.3390/pharmaceutics16121577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2024] [Revised: 12/03/2024] [Accepted: 12/06/2024] [Indexed: 01/11/2025]  Open
33
Wu D, Lin Q, Wang Z, Huang H, Song X, Gao Y, Yang X, Wen K, Sun X. Mechanism of Xue-Jie-San treating Crohn's disease complicated by atherosclerosis: Network pharmacology, molecular docking and experimental validation. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2024;135:156169. [PMID: 39488873 DOI: 10.1016/j.phymed.2024.156169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Revised: 09/29/2024] [Accepted: 10/18/2024] [Indexed: 11/05/2024]
34
Mocci G, Tursi A, Scaldaferri F, Napolitano D, Pugliese D, Capobianco I, Bartocci B, Blasi V, Savarino EV, Maniero D, Redavid C, Lorenzon G, Cuomo A, Donnarumma L, Gravina AG, Pellegrino R, Bodini G, Pasta A, Marzo M, Serio M, Scarcelli A, Rodinò S, Sebkova L, Maconi G, Cataletti G, Luppino I, Checchin D, Ferronato A, Gaiani F, Kayali S, Felice C, Pranzo G, Catarella D, D’Agostino D, Di Bartolo E, Lombardi G, Patturelli M, Bendia E, Bolognini L, Balducci D, Quatraccioni C, Martini F, Mucherino C, D’Antonio E, Montesano L, Vespere G, Sedda S, D’Onofrio V, De Luca L, Spagnuolo R, Luzza F, Fanigliulo L, Rocco G, Sacchi C, Zampaletta C, Grossi L, Lorenzetti R, Aragona G, Perazzo P, Forti G, Allegretta L, Cazzato AI, Scorza S, Cortellini F, Capone P, Villani GD, Di Fonzo M, Iacopini F, Tonti P, Neve V, Colucci R, Elisei W, Monterubbianesi R, Faggiani R, Pica R, Pagnini C, Graziani MG, Di Paolo MC, Onidi FM, Saba F, Dore MP, Satta PU, Picchio M, Papa A. Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study. J Clin Med 2024;13:7192. [PMID: 39685651 PMCID: PMC11642252 DOI: 10.3390/jcm13237192] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2024] [Revised: 11/01/2024] [Accepted: 11/08/2024] [Indexed: 12/18/2024]  Open
35
Kemp K, Samaan MA, Verma AM, Lobo AJ. Crohn's disease management: translating STRIDE-II for UK clinical practice. Therap Adv Gastroenterol 2024;17:17562848241280885. [PMID: 39526077 PMCID: PMC11544685 DOI: 10.1177/17562848241280885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Accepted: 08/19/2024] [Indexed: 11/16/2024]  Open
36
Fernandes SR, Bernardo S, Saraiva S, Rita Gonçalves A, Moura Santos P, Valente A, Araújo Correia L, Cortez-Pinto H, Magro F. Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis. Inflamm Bowel Dis 2024;30:1974-1982. [PMID: 37982426 DOI: 10.1093/ibd/izad272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Indexed: 11/21/2023]
37
Atia O, Friss C, Focht G, Magen Rimon R, Ledderman N, Ben-Tov A, Loewenberg Weisband Y, Matz E, Gorelik Y, Chowers Y, Dotan I, Turner D. Durability of Adalimumab and Infliximab in Children With Crohn's Disease: A Nationwide Comparison From the epi-IIRN Cohort. Inflamm Bowel Dis 2024;30:2097-2104. [PMID: 38190498 DOI: 10.1093/ibd/izad301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Indexed: 01/10/2024]
38
Hoelz H, Bragagna L, Litwin A, Koletzko S, Le Thi TG, Schwerd T. Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort. Inflamm Bowel Dis 2024;30:2004-2018. [PMID: 38011813 DOI: 10.1093/ibd/izad277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Indexed: 11/29/2023]
39
Gros B, Blackwell J, Segal J, Black CJ, Ford AC, Din S. Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2024;9:1030-1040. [PMID: 39307146 DOI: 10.1016/s2468-1253(24)00233-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2024] [Revised: 07/16/2024] [Accepted: 07/17/2024] [Indexed: 10/14/2024]
40
Yu N, Lee T, Tassone D, Vogrin S, Phan S, Wu DM, Zhang J, Wang L, Tjahyadi J, Dutt K, Liou H, Basnayake C, Wright E, Niewiadomski O, Lust M, Schulberg J, Kamm MA, Connell W, Thompson AJ, Hilmi I, Raja Ali RA, Wei SC, De Cruz P, Friedman AB, Moore GT, Van Langenberg D, Ding NS. 6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy. Intern Med J 2024;54:1856-1866. [PMID: 39234975 DOI: 10.1111/imj.16504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Accepted: 07/31/2024] [Indexed: 09/06/2024]
41
Moses J, Adler J, Saeed SA, Firestine AM, Galanko JA, Ammoury RF, Bass DM, Bass JA, Bastidas M, Benkov KJ, Bousvaros A, Cabrera JM, Chun KY, Dorsey JM, Ebach DR, Gulati AS, Herfarth HH, Ivanova A, Jester TW, Kaplan JL, Kusek ME, Leibowitz IH, Linville TM, Margolis PA, Minar P, Molle-Rios Z, Niklinska-Schirtz BJ, Olano KK, Osaba L, Palomo PJ, Pashankar DS, Pitch L, Samson CM, Sandberg KC, Steiner SJ, Strople JA, Sullivan JS, Tung J, Wali P, Wohl DA, Zikry M, Boyle BM, Kappelman MD. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease. Inflamm Bowel Dis 2024:izae239. [PMID: 39418336 DOI: 10.1093/ibd/izae239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Indexed: 10/19/2024]
42
Navajas Hernández P, Mouhtar el Halabi S, González Parra AC, Valdés Delgado T, Maldonado Pérez B, Castro Laria L, Charpentier C, Argüelles-Arias F. Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease. Therap Adv Gastroenterol 2024;17:17562848241278145. [PMID: 39421002 PMCID: PMC11483697 DOI: 10.1177/17562848241278145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Accepted: 08/11/2024] [Indexed: 10/19/2024]  Open
43
Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, Warusavitarne J, Agrawal M, Allocca M, Atreya R, Battat R, Bettenworth D, Bislenghi G, Brown SR, Burisch J, Casanova MJ, Czuber-Dochan W, de Groof J, El-Hussuna A, Ellul P, Fidalgo C, Fiorino G, Gisbert JP, Sabino JG, Hanzel J, Holubar S, Iacucci M, Iqbal N, Kapizioni C, Karmiris K, Kobayashi T, Kotze PG, Luglio G, Maaser C, Moran G, Noor N, Papamichael K, Peros G, Reenaers C, Sica G, Sigall-Boneh R, Vavricka SR, Yanai H, Myrelid P, Adamina M, Raine T. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2024;18:1531-1555. [PMID: 38877997 DOI: 10.1093/ecco-jcc/jjae091] [Citation(s) in RCA: 62] [Impact Index Per Article: 62.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2024] [Indexed: 07/28/2024]
44
Sigawi T, Israeli A, Ilan Y. Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies' Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders. Immunotargets Ther 2024;13:525-539. [PMID: 39431244 PMCID: PMC11488351 DOI: 10.2147/itt.s477841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2024] [Accepted: 09/27/2024] [Indexed: 10/22/2024]  Open
45
Little RD, Swaine A, Reynolds R, Gibson DJ, Barrau M, D'Errico F, Hampal R, Sparrow MP, Roblin X, Irving PM, Ward MG. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study. Inflamm Bowel Dis 2024;30:1714-1723. [PMID: 37951220 DOI: 10.1093/ibd/izad248] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Indexed: 11/13/2023]
46
Coelho T, Cheng G, Vazquez Lopez F, Ashton JJ, Beattie RM, Ennis S. Reply: Predicting Adverse Events to Thiopurines in IBD: Are We a Step Closer? Inflamm Bowel Dis 2024;30:1928-1930. [PMID: 39011772 DOI: 10.1093/ibd/izae130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 07/17/2024]
47
Lowell JA, Sharma G, Chua V, Ben-Horin S, Swaminath A, Sultan K. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis. Dig Dis Sci 2024;69:3920-3931. [PMID: 38877332 DOI: 10.1007/s10620-024-08515-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Accepted: 05/29/2024] [Indexed: 06/16/2024]
48
Roblin X, Little RD, Mathieu N, Paul S, Nancey S, Barrau M, Sparrow MP. Therapeutic drug monitoring in inflammatory bowel disease: recent developments. Expert Rev Gastroenterol Hepatol 2024;18:575-586. [PMID: 39382556 DOI: 10.1080/17474124.2024.2409300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2024] [Revised: 09/03/2024] [Accepted: 09/23/2024] [Indexed: 10/10/2024]
49
Ali S, Pasternak B, Moses J, Suskind DL, Samson C, Kaplan J, Creps J, Manning L, Baker M, Singer D, Patel P, Trombler B, Anandakrishnan A, Khorrami C, Feldman M, McGoldrick M, Adler J. Characterization of Biologic Discontinuation Among Pediatric Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2024;22:2075-2083.e1. [PMID: 38723980 DOI: 10.1016/j.cgh.2024.03.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Revised: 03/26/2024] [Accepted: 03/27/2024] [Indexed: 06/03/2024]
50
Husman J, Černá K, Matthes K, Gilger M, Arsova M, Schmidt A, Winzer N, Brosch AM, Brinkmann F, Hampe J, Zeissig S, Lukáš M, Schmelz R. Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab. Int J Colorectal Dis 2024;39:151. [PMID: 39317813 PMCID: PMC11422436 DOI: 10.1007/s00384-024-04727-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/16/2024] [Indexed: 09/26/2024]
PrevPage 1 of 9 1234589Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel